Shionogi, Inc
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- $13.1B
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
Phase 1
Terminated
- Conditions
- Bacterial Pneumonia
- Interventions
- Drug: Standard of Care Antibiotic
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 7
- Registration Number
- NCT03862040
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸North Western University, Chicago, Illinois, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
- Conditions
- Bacterial Infections
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Shionogi
- Registration Number
- NCT03780140
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 151
- Registration Number
- NCT03395353
- Locations
- 🇯🇵
Shionogi, Osaka, Japan
A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder
Phase 3
Completed
- Conditions
- Depressive Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 149
- Registration Number
- NCT03315793
- Locations
- 🇯🇵
Shionogi, Osaka, Japan
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
Phase 3
Completed
- Conditions
- Healthcare-associated Pneumonia (HCAP)Ventilator Associated Pneumonia (VAP)Hospital Acquired Pneumonia (HAP)
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 300
- Registration Number
- NCT03032380
- Locations
- 🇺🇦
Shionogi Research Site, Zaporizhzhya, Ukraine
A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 1436
- Registration Number
- NCT02954354
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 2184
- Registration Number
- NCT02949011
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Phase 3
Completed
- Conditions
- Hospital Acquired Pneumonia (HAP)Complicated Urinary Tract Infection (cUTI)Ventilator Associated Pneumonia (VAP)Healthcare-associated Pneumonia (HCAP)SepsisBloodstream Infections (BSI)
- Interventions
- Drug: Best Available Therapy
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 152
- Registration Number
- NCT02714595
- Locations
- 🇬🇧
Shionogi Research Site, London, England, United Kingdom
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 631
- Registration Number
- NCT02638337
Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Phase 3
Completed
- Conditions
- ThrombocytopeniaChronic Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 215
- Registration Number
- NCT02389621
© Copyright 2025. All Rights Reserved by MedPath